SABS
SAB Biotherapeutics, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 10 ▲ SAB Biotherapeutics released Phase 1 data for its investigational th…
- Mar 17 ▼ SAB Biotherapeutics (SABS) has announced the commencement of an unde…
- Mar 18 ▼ SAB Biotherapeutics (SABS) announced the pricing of a public offerin…
- Mar 19 ▼ SAB Biotherapeutics is conducting a public offering of 19.3 million…
- May 12 ▼ SAB Biotherapeutics reported Q1 2026 EPS of -$0.35, a 68.3% miss vs…
- May 22 Citigroup initiates
- May 29 FDA: SAB BIO to Present Data on SAB-142 at The American Diabete…
- Jun 24 Barclays initiates
- Jul 7 Contract: Breakthrough T1D Awards Grant to Support PRISE‑hATG Study…
- Oct 13 ▲ SAB Biotherapeutics announced FDA Fast Track designation for SAB-142…
- Oct 13 FDA: SAB BIO Receives FDA Fast Track Designation for SAB-142 in…
- Nov 5 ▲ Earnings: SABS Q3 2026 Earnings: EPS $-0.24 (+12.9% vs est)
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsBULLISH
Q3 2026: 19 added (0 new), 6 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.272 → −$0.244 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest +4.7% to 5.03M shares. 8.3 days to cover, ≈5.6% of shares.
- TrendRANGE
3% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| STATE STREET CORP | ADD | $2.3M |
| UBS Group AG | ADD | $1.7M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | $1.2M |
| ALPS ADVISORS INC | ADD | $379.4K |
| AMERICAN CENTURY COMPANIES INC | ADD | $346.3K |
| MORGAN STANLEY | DOUBLED | $285.6K |
| JPMORGAN CHASE & CO | ADD | $101.6K |
| Vanguard Global Advisers, LLC | ADD | $73.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Jun 2026Price is below the lowest target. Median implies +300%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Jun 24, 2026 | Barclays INITIATE | Overweight |
| Jun 17, 2026 | Chardan Capital MAINTAIN | Buy |
| Jun 15, 2026 | Leerink Partners MAINTAIN | Outperform |
| Jun 15, 2026 | HC Wainwright & Co. REITERATE | Buy |
| May 22, 2026 | Citigroup INITIATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Kropotova Alexandra CHIEF MEDICAL OFFICER Sep 17, 2026 | TAX W/H | 473 sh |
Kropotova Alexandra CHIEF MEDICAL OFFICER Jun 25, 2026 | TAX W/H | 988 sh |
Kropotova Alexandra CHIEF MEDICAL OFFICER Mar 24, 2026 | TAX W/H | 988 sh |
Sullivan Eddie Joe PRESIDENT Feb 3, 2026 | AWARD | 3,000,000 sh |
Bausch Christoph Lawrence CHIEF OPERATING OFFICER Feb 3, 2026 | AWARD | 1,800,000 sh |
Kropotova Alexandra CHIEF MEDICAL OFFICER Feb 3, 2026 | AWARD | 2,400,000 sh |
To Lucy See Remarks Feb 3, 2026 | AWARD | 2,400,000 sh |
Reich Samuel J CEO Feb 3, 2026 | AWARD | 4,800,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.24 | -$0.31–-$0.19 | +10.0% | $0.00 |
| Next Q | -$0.25 | -$0.32–-$0.21 | -21.3% | $0.00 |
| Current FY | -$1.13 | -$1.16–-$1.06 | +3.2% | $0.00 |
| Next FY | -$0.94 | -$1.20–-$0.60 | +1.3% | $62.5K |
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 6 press releases · 2 bullish · 2 bearish · 5 neutral- NEUTRAL SC 13G/ANov 16, 2026
Woodline Partners LP filed an amended Schedule 13G disclosing a 5.7% passive beneficial ownership stake in SAB Biotherapeutics, Inc., consisting of 5,455,694 shares on a fully-converted basis (including common stock, Series B Preferred Stock, Enrollment Warrants and Data Release Warrants). This is…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Vivo Opportunity Fund Holdings, L.P. filed an amended Schedule 13G disclosing a 9.99% passive beneficial ownership stake in SAB Biotherapeutics, Inc., consisting of 22,287,501 shares on a fully-converted basis (including common stock, Series B Preferred Stock, Enrollment Warrants and Data Release…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL SC 13G/ANov 16, 2026
Balyasny Asset Management L.P. filed an amended Schedule 13G disclosing a 7.94% passive stake in SAB Biotherapeutics, Inc., consisting of 7,225,439 shares (including 3,465,000 shares issuable upon warrant exercise). The stake is unchanged from the prior filing on August 14, 2026, which also…
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL PRESS-RELEASENov 5, 2026
SAB Biotherapeutics reported a Q3 2026 net loss of $22.3M vs net income of $45.4M a year ago…
Monitor SAFEGUARD enrollment completion (expected Q4 2026) and topline data in 2H 2027 as the primary catalysts. The Fast Track designation may accelerate regulatory interactions but does not…
All SABS filing & press-release reports (15)
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- PRESS-RELEASE reportNov 5, 2026
- 25-NSE reportOct 22, 2026
- 8-K reportOct 13, 2026
- PRESS-RELEASE reportOct 13, 2026
- 8-K reportJul 7, 2026
- PRESS-RELEASE reportMay 29, 2026
- PRESS-RELEASE reportMay 12, 2026
- PRESS-RELEASE reportMar 19, 2026
- 8-K reportMar 19, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 17, 2026
- PRESS-RELEASE reportMar 10, 2026